

Texas Vendor Drug Program

Drug Use Criteria: Atypical Antipsychotics (oral)

Publication History

1. Developed: February 1997
2. Revised: September 2017; September 2015; December 2013; February 2012; June 2010; May 2010; March 2007; December 2006; October 2006; May 2003; April 2002; April 2001; April 2000; March 1999; March 1998.

Notes: Information on indications for use or diagnosis is assumed to be unavailable. All criteria may be applied retrospectively; prospective application is indicated with an asterisk [*]. The information contained is for the convenience of the public. The Texas Health and Human Services Commission is not responsible for any errors in transmission or any errors or omissions in the document.

Medications listed in the tables and non-FDA approved indications included in these retrospective criteria are not indicative of Vendor Drug Program formulary coverage.

Prepared by:

- Drug Information Service, UT Health San Antonio.
- The College of Pharmacy, The University of Texas at Austin.

1 Dosage

1.1 Adults

Oral atypical antipsychotics are FDA-approved for use in schizophrenia, bipolar I disorder (BD), bipolar disorder with mixed episodes or depressive episodes, bipolar mania, schizoaffective disorder (SD), adjunctive therapy in major depressive



TEXAS
Health and Human
Services

Medical and
Social Services

disorder (MDD), treatment-resistant schizophrenia, and irritability associated with autism.¹⁻¹⁸ **Cariprazine (Vraylar®) has recently been approved for schizophrenia and manic or mixed episodes associated with BD.**^{1-4, 19}

Pimavanserin (Nuplazid®) is an oral atypical antipsychotic recently indicated for use to manage hallucinations and delusions seen with Parkinson’s disease psychosis.^{1-4, 20} Olanzapine combination therapy is FDA-approved for use in managing treatment-resistant depression as well as bipolar depression.^{1-4, 21}

Maximum recommended adult doses for atypical antipsychotics are summarized in Table 1. Dosages exceeding these recommendations will be reviewed.

Table 1. Oral Atypical Antipsychotics (Monotherapy) - Adult Maximum Recommended Dosages¹⁻³⁹

Treatment Indication	Drug Name	Available Dosage Strengths	Maximum Recommended Dosage
Schizophrenia, BD	Aripiprazole (Abilify®), Abilify Discmelt®)	2 mg, 5 mg, 10mg, 15 mg, 20 mg, 30 mg immediate-release (IR) tablets 10 mg, 15 mg orally disintegrating tablets (ODTs) 1 mg/ml oral solution	30 mg/day
MDD	Aripiprazole (Abilify®, Abilify Discmelt®)	2 mg, 5 mg, 10mg, 15 mg, IR tablets 10 mg, 15 mg ODTs 1 mg/ml oral solution	15 mg/day
Schizophrenia, BD	Asenapine (Saphris®)	2.5 mg , 5 mg, 10 mg sublingual tablets	20 mg/day, in two divided doses
Schizophrenia	Brexpiprazole (Rexulti®)	0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg tablets	4 mg once daily

Treatment Indication	Drug Name	Available Dosage Strengths	Maximum Recommended Dosage
MDD	Brexpiprazole (Rexulti®)	0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg tablets	3 mg once daily
BD (acute mixed/manic episodes), schizophrenia	Cariprazine (Vraylar®)	1.5 mg, 3 mg, 4.5 mg 6 mg capsules	6 mg once daily
Schizophrenia (treatment-resistant), reducing recurrent suicidal behavior in schizophrenia and SD	Clozapine (Clozaril®, generics, FazaClo®, Versacloz®)	25 mg, 50 mg, 100 mg, 200 mg IR tablets 12.5 mg, 25 mg, 100 mg, 150 mg, 200 mg ODTs 50 mg/ml oral suspension	900 mg/day, in divided doses
Schizophrenia	Iloperidone (Fanapt®)	1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg 12 mg IR tablets	24 mg/day, in divided doses
Schizophrenia	Lurasidone (Latuda®)	20 mg, 40 mg, 60 mg, 80 mg, 120 mg IR tablets	160 mg/day, with food (at least 350 calories)
Bipolar depression	Lurasidone (Latuda®)	20 mg, 40 mg, 60 mg, 80 mg, 120 mg IR tablets	120 mg/day, with food (at least 350 calories)
Schizophrenia, BD, treatment-resistant depression	Olanzapine (Zyprexa®, Zyprexa Zydys®, generics)	2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg IR tablets 5 mg, 10 mg, 15 mg, 20 mg orally disintegrating tablets	20 mg/day, as a single dose
Schizophrenia, SD	Paliperidone (Invega®)	1.5 mg, 3 mg, 6 mg, 9 mg extended-release (ER) tablets	12 mg/day

Treatment Indication	Drug Name	Available Dosage Strengths	Maximum Recommended Dosage
Parkinson disease psychosis	Pimavanserin (Nuplazid®)	17 mg tablet	34 mg once daily
Schizophrenia, BD (acute manic episodes, maintenance)	Quetiapine (Seroquel®, Seroquel XR®, generics)	25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg IR tablets 50 mg, 150 mg, 200 mg, 300 mg, 400 mg ER tablets	IR: 800 mg/day, in two or three divided doses ER: 800 mg/day, as a single dose
MDD	Quetiapine (Seroquel®, Seroquel XR®, generics)	50 mg, 150 mg, 200 mg, 300 mg, 400 mg ER tablets	ER: 300 mg/day, as a single dose
Bipolar depression	Quetiapine (Seroquel®, Seroquel XR®, generics)	25 mg, 50 mg, 100 mg, 200 mg, 300 mg IR tablets 50 mg, 150 mg, 200 mg, 300 mg ER tablets	IR: 300 mg/day, at bedtime ER: 300 mg/day, as a single dose
Schizophrenia	Risperidone (Risperdal®, Risperdal M-TAB®, generics)	0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg IR tablets 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg ODTs 1 mg/ml oral solution	8 mg/day*
Bipolar mania	Risperidone (Risperdal®, Risperdal M-TAB®, generics)	0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg IR tablets 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg ODTs 1 mg/ml oral solution	6 mg/day

Treatment Indication	Drug Name	Available Dosage Strengths	Maximum Recommended Dosage
Schizophrenia	Ziprasidone (Geodon®, generics)	20 mg, 40 mg, 60 mg, 80 mg IR capsules	200 mg/day, in two divided doses ⁺
BD	Ziprasidone (Geodon®, generics)	20 mg, 40 mg, 60 mg, 80 mg IR capsules	160 mg/day, in two divided doses

** doses up to 16 mg/day have demonstrated efficacy in clinical trials; however, doses of 4 to 8 mg/day tended to produce the maximal effect*

****doses up to 320 mg daily have been used safely but greater efficacy not noted with higher dosages***

Combination therapy with the atypical antipsychotic, olanzapine, and the selective serotonin reuptake inhibitor, fluoxetine, is FDA-approved for the management of depressive episodes associated with bipolar I disorder and treatment-resistant depression in adults. Doses exceeding the maximum adult recommended doses summarized in Table 2 will be reviewed.

Table 2. Oral Atypical Antipsychotics (Combination Therapy) – Adult Maximum Recommended Dosages^{1-4, 40}

Treatment Indication	Drug Name	Available Dosage Strengths	Maximum Recommended Dosage
Bipolar depression, treatment-resistant depression	Olanzapine/fluoxetine (Symbyax®)	Olanzapine 3 mg/fluoxetine 25 mg; olanzapine 6 mg/fluoxetine 25 mg; olanzapine 6 mg/fluoxetine 50 mg; olanzapine 12 mg/fluoxetine 25 mg; olanzapine 12 mg/fluoxetine 50 mg	Olanzapine 18 mg/ fluoxetine 75 mg once daily in evening, without regard to meals

1.2 Pediatrics

Risperidone has been FDA-approved to manage symptoms of irritability in autistic children > 5 years of age and adolescents, and has recently gained FDA-approved indications for bipolar mania in children and adolescents 10 to 17 years of age and schizophrenia in adolescents 13 to 17 years of age. Aripiprazole has received recent FDA approval for treating Tourette's disorder in pediatric patients 6 to 18 years of age, and is also FDA-approved for managing schizophrenia in adolescents 13 to 17 years of age, bipolar disorder with or without psychotic features in children 10 to 17 years of age, and irritability associated with autistic disorder in children 6 to 17 years of age. Olanzapine has been granted FDA approval for bipolar disorder and schizophrenia in adolescents 13 years of age and older, while quetiapine received FDA approval for acute treatment of bipolar disorder mania episodes in children and adolescents 10 to 17 years of age and schizophrenia management in adolescents 13 to 17 years of age. Paliperidone has recently gained FDA approval for schizophrenia in adolescents 12 to 17 years of age. Brexpiprazole, **cariprazine**, clozapine, iloperidone, lurasidone, and ziprasidone are not recommended for use in pediatric patients as safety and efficacy have not been established in this patient population. **Additionally, pimavanserin is not approved for use in pediatric patients as Parkinson's disease is typically not observed in pediatric patients, and safety and efficacy data are not available for pimavanserin in the pediatric population.** Atypical antipsychotic pediatric dosages are summarized in Table 3.¹⁻⁴

Table 3. Atypical Antipsychotics (Monotherapy) – Pediatric Maximum Recommended Dosages^{1-4, 8, 10, 12-16}

Treatment Indication	Drug Name	Available Dosage Strengths	Maximum Recommended Dosage per Age Group
Schizophrenia	Aripiprazole(Abilify® , Abilify Discmelt®)	2 mg, 5 mg, 10mg, 15 mg, 20 mg, 30 mg immediate-release (IR) tablets 10 mg, 15 mg orally disintegrating tablets (ODTs) 1 mg/ml oral solution	<i>13-17 years of age:</i> 30 mg once daily
BD	Aripiprazole(Abilify® , Abilify Discmelt®)	2 mg, 5 mg, 10mg, 15 mg, 20 mg, 30 mg IR tablets 10 mg, 15 mg ODTs 1 mg/ml oral solution	<i>10-17 years of age:</i> 30 mg once daily
Irritability associated with autism	Aripiprazole(Abilify® , Abilify Discmelt®)	2 mg, 5 mg, 10mg, 15 mg, IR tablets 10 mg, 15 mg ODTs 1 mg/ml oral solution	<i>6-17 years of age:</i> 15 mg/day as a single dose
Tourette's disorder	Aripiprazole(Abilify® , Abilify Discmelt®)	2 mg, 5 mg, 10mg, 15 mg, 20 mg, 30 mg IR tablets 10 mg, 15 mg ODTs 1 mg/ml oral solution	<i>6-18 years of age:</i> < 50 kg: 10 mg/day ≥ 50 kg: 20 mg/day
BD	Asenapine (Saphris®)	5 mg, 10 mg sublingual tablets	<i>10-17 years of age:</i> 20 mg/day, in two divided doses

Treatment Indication	Drug Name	Available Dosage Strengths	Maximum Recommended Dosage per Age Group
Schizophrenia, BD	Olanzapine (Zyprexa®, Zyprexa Zydys®, generics)	2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg IR tablets 5 mg, 10 mg, 15 mg, 20 mg orally disintegrating tablets	13 to 17 years of age: 20 mg once daily
Schizophrenia	Paliperidone (Invega®)	1.5 mg, 3 mg, 6 mg, 9 mg extended-release (ER) tablets	12-17 years of age: < 51 kg: 6 mg/day ≥ 51 kg: 12 mg/day
BD - acute manic episodes	Quetiapine (Seroquel®, generics, Seroquel XR®)	25 mg, 50 mg, 100 mg 200 mg, 300 mg, 400 mg IR tablets 50 mg, 150 mg, 200 mg, 300 mg, 400 mg ER tablets	10 to 17 years of age: 600 mg daily, once daily (ER tablets) or in 2 to 3 divided doses (IR tablets)
Schizophrenia	Quetiapine (Seroquel®, generics, Seroquel XR®)	25 mg, 50 mg, 100 mg 200 mg, 300 mg, 400 mg IR tablets 50 mg, 150 mg, 200 mg, 300 mg, 400 mg ER tablets	13 to 17 years of age: 800 mg daily, once daily (ER tablets) or in 2 to 3 divided doses (IR tablets)
Bipolar mania	Risperidone (Risperdal®, Risperdal M-TAB®, generics)	0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg IR tablets 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg ODTs 1 mg/ml oral solution	10-17 years of age: 6 mg daily

Treatment Indication	Drug Name	Available Dosage Strengths	Maximum Recommended Dosage per Age Group
Schizophrenia	Risperidone (Risperdal®, Risperdal M-TAB®, generics)	0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg IR tablets 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg ODTs 1 mg/ml oral solution	13-17 years of age: 6 mg daily
Irritability in autistic disorder	Risperidone (Risperdal®, Risperdal M-TAB®, generics)	0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg IR tablets 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg ODTs 1 mg/ml oral solution	5-17 years of age: 3 mg/day (no dosing data available for pediatric patients < 15 kg)

The olanzapine/fluoxetine combination has been approved for use in pediatric patients 10-17 years of age with depression associated with BD. Recommended pediatric dosages are summarized in Table 4.

Table 4. Oral Atypical Antipsychotics (Combination Therapy) – Pediatric Maximum Recommended Dosages^{1-4, 40}

Treatment Indication	Drug Name	Available Dosage Strengths	Maximum Recommended Dosage per Age Group
Bipolar depression	Olanzapine/fluoxetine (Symbyax®)	Olanzapine 3 mg/fluoxetine 25 mg; olanzapine 6 mg/fluoxetine 25 mg; olanzapine 6 mg/fluoxetine 50 mg; olanzapine 12 mg/fluoxetine 25 mg; olanzapine 12 mg/fluoxetine 50 mg	10-17 years of age: olanzapine 12 mg/fluoxetine 50 mg once daily in evening, without regard to meals

2 Duration of Therapy ¹⁻⁴⁰

Atypical antipsychotics are indicated for use in the management of schizophrenia and psychotic disorders. Therefore, there is no basis for limiting treatment duration with these atypical antipsychotics as these agents are utilized in the management of chronic disorders.

3 Duplicative Therapy

Combined therapy with multiple antipsychotic medications has been evaluated in patients with treatment-resistant schizophrenia. Open studies, case reports, and clinical trials have observed favorable results following concurrent therapy with either atypical antipsychotics plus conventional antipsychotic agents, or clozapine in conjunction with an additional atypical antipsychotic in clozapine-refractory patients. Further controlled trials are necessary to identify patients and circumstances in which combination therapy should be utilized as well as risks and benefits of concurrent therapy.

Neuroleptics should be used concomitantly during transitional periods lasting up to four weeks when switching patients to a different antipsychotic agent.

4 Drug-Drug Interactions

Patient profiles will be assessed to identify those drug regimens which may result in clinically significant drug-drug interactions. Drug interactions considered clinically relevant for atypical antipsychotics are summarized in Table 5. Only those drug-drug interactions classified as clinical significance level 1 or those considered life-threatening which have not yet been classified will be reviewed:

Table 5. Select Drug-Drug Interactions for Oral Atypical Antipsychotics^{1-4, 41}

Target Drug	Interacting Drug	Interaction	Recommendation	Clinical Significance Level [#]
Aripiprazole	Citalopram	Increased risk of QT prolongation and serotonin syndrome because aripiprazole is a partial agonist of 5-HT _{1A} and citalopram is a selective serotonin reuptake inhibitor	Avoid use	Major (DrugReax) 2-major(CP)
Atypical antipsychotics (AAs)	Antihypertensive agents	Potential for enhanced antihypertensive effects due to AA-associated alpha ₁ -adrenergic receptor antagonism	Use cautiously together; monitor for amplified hypotensive effects	3-moderate (CP)
AAs	CNS depressants	Potential for additive CNS effects	Use cautiously together; observe patients for enhanced CNS adverse effects	Major (DrugReax) 3-moderate (CP)
AAs (except pimavanserin)	Drugs affecting seizure threshold (e.g., tramadol)	Increased seizure risk as AAs have been associated with seizures (incidence varies)	Avoid drug combination if possible; if combination necessary, closely monitor patients for seizure activity and discontinue therapy as indicated	Major (DrugReax) 2-major (CP)

Target Drug	Interacting Drug	Interaction	Recommendation	Clinical Significance Level [#]
AAs	Metoclopramide	Adjunctive therapy enhances potential for increased extrapyramidal symptoms (EPS) and neuroleptic malignant syndrome (NMS) as both agents block dopamine receptors	Combination contraindicated by metoclopramide manufacturer; if combination necessary, monitor for signs/symptoms of EPS or NMS-discontinue metoclopramide if symptoms develop	Contraindicated (DrugReax) 1-severe (CP)
Clozapine	Myelosuppressive (antineoplastic) drugs	Potential for additive bone marrow suppressive effects	Concurrent administration contraindicated	1-severe (CP)
Clozapine	Carbamazepine	Increased risk of additive bone marrow-suppressing effects, including agranulocytosis	Avoid concurrent use; choose alternative anticonvulsant	Major (DrugReax) 2-major (CP)
Select AAs (clozapine, olanzapine)	CYP1A2 inducers (e.g., carbamazepine ^{**} , phenobarbital, phenytoin, ritonavir [*] , rifampin)	Potential for reduced clozapine, olanzapine serum concentrations and worsening of psychosis	Monitor clozapine, olanzapine efficacy in patients; adjust doses as necessary when CYP1A2 inducer added, deleted, or changed to therapeutic regimen	Moderate (DrugReax) 2-major (CP)

Target Drug	Interacting Drug	Interaction	Recommendation	Clinical Significance Level [#]
Select AAs (asenapine, clozapine, olanzapine)	CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine)	Potential for decreased AA clearance, increased AA serum concentrations and enhanced pharmacologic/adverse effects (seizures, hypotension) as clozapine, olanzapine metabolized by CYP1A2	If drug combination necessary, used reduced clozapine dosages and closely monitor for adverse events	Moderate (DrugReax) 2-major (CP)
Select AAs (aripiprazole, brexpiprazole, cariprazine, clozapine, iloperidone, pimavanserin, quetiapine, ziprasidone)	CYP3A4 inhibitors (e.g., ketoconazole, ritonavir*)	Potential for decreased AA clearance, increased AA serum concentrations, and enhanced pharmacologic/adverse effects as select AAs metabolized by CYP3A4	Monitor for enhanced AA pharmacologic/adverse effects and adjust doses as necessary (50% dose reduction recommended for aripiprazole, brexpiprazole, iloperidone)	Moderate (DrugReax) 2-major, 3-moderate (CP)
Select AAs (aripiprazole, brexpiprazole, clozapine, olanzapine, pimavanserin, quetiapine, risperidone, ziprasidone)	CYP3A4 inducers (e.g., carbamazepine**, phenytoin)	Potential for significant reductions in AA plasma concentrations (by as much as 50%) due to enhanced AA hepatic microsomal metabolism	Monitor AA efficacy in patients; adjust doses as necessary when CYP3A4 inducer added, deleted, or changed to therapeutic regimen (brexpiprazole dose should be doubled over 1-2 weeks when prescribed with CYP3A4 inducer)	Moderate (DrugReax) 2-major , 3-moderate (CP)

Target Drug	Interacting Drug	Interaction	Recommendation	Clinical Significance Level [#]
Select AAs (aripiprazole, brexpiprazole, iloperidone, risperidone)	CYP2D6 inhibitors (e.g., quinidine, select SSRIs, ritonavir)	Potential for decreased AA clearance and increased AA serum concentrations and enhanced pharmacologic/adverse effects as select AAs metabolized by CYP2D6	Monitor for enhanced AA pharmacologic/adverse effects and adjust doses as necessary (recommended to reduce aripiprazole, brexpiprazole, iloperidone doses by 50% when administered in conjunction with CYP2D6 inhibitor)	Moderate (DrugReax) 2-major, 3-moderate (CP)
Select AAs (aripiprazole, asenapine, clozapine, iloperidone, olanzapine, paliperidone, pimavanserin, quetiapine, risperidone, ziprasidone)	QTc interval-prolonging medications	Potential for increased cardiotoxicity (e.g., torsades de pointes, cardiac arrest) due to additive QT interval prolongation	Avoid concurrent use; if combination necessary, closely monitor cardiac function; discontinue therapy in patients with QTc measurements > 500 msec	Major (DrugReax) 1-severe, 2-major (CP)

[#]CP = Clinical Pharmacology

*Ritonavir inhibits clozapine metabolism through CYP3A4 inhibition, but induces olanzapine metabolism through CYP1A2 enzyme induction.

**Carbamazepine induces olanzapine metabolism through CYP1A2 enzyme induction and induces clozapine metabolism through CYP3A4 induction.

5 References

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; 2017. Available at: <http://www.clinicalpharmacology.com>. Accessed September 20th, 2017.
2. AHFS Drug Information 2017 [book online]. Jackson, WY: Teton Data Systems, Version 8.9.0, 2017. Stat!Ref Electronic Medical Library. Available at: <http://online.statref.com.libproxy.uthscsa.edu>. Accessed September 20th, 2017.

3. DRUGDEX® System (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Available at: <http://www.micromedexsolutions.com.libproxy.uthscsa.edu>. **Accessed September 20th, 2017.**
4. **Facts and Comparisons eAnswers [database online]. Hudson, Ohio: Wolters Kluwer Clinical Drug Information, Inc.; 2017. Available at: <http://eanswers.factsandcomparisons.com.ezproxy.lib.utexas.edu/>. Accessed September 22nd, 2017.**
5. Clozapine tablets (Clozaril®) package insert. Novartis Pharmaceuticals Corporation, **February 2017.**
6. Clozapine orally disintegrating tablets (FazaClo®) package insert. Jazz Pharmaceuticals, Inc., **February 2017.**
7. Clozapine oral suspension (Versacloz®) package insert. Jazz Pharmaceuticals, Inc., **September 2015.**
8. Asenapine sublingual tablets (Saphris®) package insert. **Allergan USA, Inc., February 2017.**
9. Ziprasidone capsules (Geodon®) package insert. Pfizer, **February 2017.**
10. Risperidone tablets, orally disintegrating tablets, oral solution (Risperdal®) package insert. Janssen Pharmaceuticals, Inc., **February 2017.**
11. Iloperidone tablets (Fanapt®) package insert. **Vanda Pharmaceuticals Inc., February 2017.**
12. Paliperidone extended-release tablets (Invega®) package insert. Janssen Pharmaceuticals, Inc., **July 2017.**
13. Aripiprazole tablet, orally disintegrating tablet, oral solution (Abilify®) package insert. Otsuka America Pharmaceutical, Inc., **February 2017.**
14. Olanzapine tablet, orally disintegrating tablet (Zyprexa®, Zyprexa® Zydis®) package insert. Eli Lilly and Company, **January 2017.**
15. Quetiapine tablets (Seroquel®) package insert. AstraZeneca Pharmaceuticals, **February 2017.**
16. Quetiapine extended-release tablets (Seroquel XR®) package insert. AstraZeneca Pharmaceuticals, **February 2017.**
17. Lurasidone tablets (Latuda®) package insert. Sunovion Pharmaceuticals Inc., **February 2017.**
18. Brexpiprazole (Rexulti®) package insert. Otsuka America Pharmaceutical, Inc., **February 2017.**
19. **Cariprazine capsules (Vraylar®) package insert. Allergan USA, Inc., February 2017.**
20. **Pimavanserin tablets (Nuplazid®) package insert. Acadia Pharmaceuticals, Inc., April 2017.**
21. Komossa K, Rummel-Kluge C, Hunger H, et al. Ziprasidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2009, Issue 4. Art. No.: CD006627.
22. Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry. 2009;166(9):980-91.

23. Cruz N, Sanchez-Moreno J, Torres F, et al. Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis. *Int J Neuropsychopharmacol.* 2010;13(1):5-14.
24. Crossley NA, Constante M, McGuire P, Power P. Efficacy of atypical v. typical antipsychotics in the treatment of early psychosis: meta-analysis. *Br J Psychiatry.* 2010;196:434-9.
25. Edwards SJ, Smith CJ. Tolerability of atypical antipsychotics in the treatment of adults with schizophrenia or bipolar disorder: a mixed treatment comparison of randomized controlled trials. *Clin Ther.* 2009;31(Part 1):1345-59.
26. Vitiello B, Correll C, van Zwieten-Boot B, et al. Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns. *Eur Neuropsychopharmacol.* 2009;19(9):629-35.
27. Sernyak MJ, Rosenheck R. Clinicians' reasons for antipsychotic coprescribing. *J Clin Psychiatry.* 2004;65:1597-1600.
28. Tapp AM, Wood AE, Kilzieh N, et al. Antipsychotic polypharmacy: do benefits justify the risks? *Ann Pharmacother.* 2005;39:1759-60.
29. Tranulis C, Skalli L, Lalonde P, et al. Benefits and risks of antipsychotic polypharmacy: an evidence-based review of the literature. *Drug Saf.* 2008;31(1):7-20.
30. Cheng-Shannon J, McGough JJ, Pataki C, McCracken JT. Second-generation antipsychotic medications in children and adolescents. *J Child Adolesc Psychopharmacol.* 2004;14:372-94.
31. Barzman DH, DeBello MP, Kowatch RA, et al. The effectiveness and tolerability of aripiprazole for pediatric bipolar disorders: a retrospective chart review. *J Child Adolesc Psychopharmacol.* 2004;14:593-600.
32. Kranzler H, Roofeh D, Gerbino-Rosen G, et al. Clozapine: its impact on aggressive behavior among children and adolescents with schizophrenia. *J Am Acad Child Adolesc Psychiatry.* 2005;44:55-63.
33. Sikich L, Hamer RM, Bashford RA, et al. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. *Neuropsychopharmacology.* 2004;29:133-45.
34. Mozes T, Greenberg Y, Spivak B, et al. Olanzapine treatment in chronic drug-resistant childhood-onset schizophrenia: an open-label study. *J Child Adolesc Psychopharmacol.* 2003;13:311-7.
35. Delbello MP, Schwiers ML, Rosenberg HL, Strakowski SM. A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. *J Am Acad Child Adolesc Psychiatry.* 2002;41:1216-23.
36. Barnett MS. Ziprasidone monotherapy in pediatric bipolar disorder. *J Child Adolesc Psychopharmacol.* 2004;14:471-7.
37. Aman MG, Arnold LE, McDougle CJ, et al. Acute and long-term safety and tolerability of risperidone in children with autism. *J Child Adolesc Psychopharmacol.* 2005;15:869-84.
38. Masi G, Liboni F. Management of schizophrenia in children and adolescents: focus on pharmacotherapy. *Drugs.* 2011;71(2):179-208.

39. Thomas T, Stansifer L, Findling RL. Psychopharmacology of pediatric bipolar disorders in children and adolescents. *Pediatr Clin N Am.* 2011;58:173-87.
40. Olanzapine and fluoxetine hydrochloride capsule (Symbyax®) package insert. Eli Lilly and Company, **March 2017.**
41. DRUG-REAX® System (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Available at: <http://www.micromedexsolutions.com.libproxy.uthscsa.edu>. **Accessed September 20th, 2017.**